PA8551001A1 - Nuevos compuestos - Google Patents

Nuevos compuestos

Info

Publication number
PA8551001A1
PA8551001A1 PA20028551001A PA8551001A PA8551001A1 PA 8551001 A1 PA8551001 A1 PA 8551001A1 PA 20028551001 A PA20028551001 A PA 20028551001A PA 8551001 A PA8551001 A PA 8551001A PA 8551001 A1 PA8551001 A1 PA 8551001A1
Authority
PA
Panama
Prior art keywords
compounds
new compounds
formula
preparation
medicines
Prior art date
Application number
PA20028551001A
Other languages
English (en)
Inventor
Fujii Toshihiko
Okada Takehiro
Taniguchi Mikio
Watanabe Fumio
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PA8551001A1 publication Critical patent/PA8551001A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVOS COMPUESTOS DE FORMULA 1, CON ACTIVIDAD ANTI-TUMORAL, EN DONDE R1,R2,R3,R4,R5 Y N SON TAL COMO SE DESCRIBEN EN LA DESCRIPCION Y LAS REIVINDICACIONES Y LAS SALES FARMACEUTICAMENTE ACEPTABLES DE LAS MISMAS. LA PRESENTE INVENCION CONCIERNE TAMBIEN A LA COMPOSICION FARMACEUTICA QUE COMPRENDE COMPUESTOS DE FORMULA (1), EL USO DE COMPUESTOS DE FORMULA (1) PARA LA PREPARACION DE MEDICAMENTOS Y PROCESOS PARA LA PREPARACION DE COMPUESTOS (1).
PA20028551001A 2001-07-19 2002-07-18 Nuevos compuestos PA8551001A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01117410 2001-07-19

Publications (1)

Publication Number Publication Date
PA8551001A1 true PA8551001A1 (es) 2003-09-17

Family

ID=8178073

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20028551001A PA8551001A1 (es) 2001-07-19 2002-07-18 Nuevos compuestos

Country Status (30)

Country Link
US (1) US6737409B2 (es)
EP (1) EP1412328B1 (es)
JP (1) JP2004534859A (es)
KR (2) KR100611540B1 (es)
CN (1) CN1553897A (es)
AR (1) AR036175A1 (es)
AT (1) ATE341537T1 (es)
BR (1) BR0211289A (es)
CA (1) CA2453987A1 (es)
CO (1) CO5550462A2 (es)
DE (1) DE60215179T2 (es)
DK (1) DK1412328T3 (es)
ES (1) ES2272763T3 (es)
GT (1) GT200200154A (es)
HR (1) HRP20040043A2 (es)
HU (1) HUP0401253A2 (es)
IL (1) IL159890A0 (es)
MX (1) MXPA04000577A (es)
MY (1) MY127718A (es)
NO (1) NO20040198L (es)
NZ (1) NZ530655A (es)
PA (1) PA8551001A1 (es)
PE (1) PE20030258A1 (es)
PL (1) PL367682A1 (es)
PT (1) PT1412328E (es)
RU (1) RU2296750C2 (es)
SI (1) SI1412328T1 (es)
UY (1) UY27388A1 (es)
WO (1) WO2003008378A1 (es)
ZA (1) ZA200400334B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7064211B2 (en) 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
AU2003228354B8 (en) 2002-03-22 2010-03-04 Eisai R&D Management Co., Ltd. Hemiasterlin derivatives and uses thereof in the treatment of cancer
EP1545613B9 (en) 2002-07-31 2012-01-25 Seattle Genetics, Inc. Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
KR101520209B1 (ko) 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
WO2005118525A1 (en) * 2004-06-02 2005-12-15 F.Hoffmann-La Roche Ag Synthesis of amino-alkoxy-heptanoic alkyl ester
US8288352B2 (en) 2004-11-12 2012-10-16 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the N terminus
RU2007126358A (ru) * 2004-12-13 2009-01-20 Ф.Хоффманн-Ля Рош Аг (Ch) Новая фармацевтическая композиция, содержащая по меньшей мере одно производное доластатина 10
CN101076515A (zh) * 2004-12-13 2007-11-21 霍夫曼-拉罗奇有限公司 制备3－吡咯烷－2－基－丙酸衍生物的新方法
US20060189893A1 (en) * 2005-01-06 2006-08-24 Diamics, Inc. Systems and methods for detecting abnormal cells
US20060161076A1 (en) * 2005-01-06 2006-07-20 Diamics, Inc. Systems and methods for collection of cell clusters
WO2006074873A2 (en) * 2005-01-13 2006-07-20 F. Hoffmann-La Roche Ag New one-step synthesis of useful disubstituted amines
WO2006122408A1 (en) 2005-05-18 2006-11-23 Aegera Therapeutics Inc. Bir domain binding compounds
CA2614436C (en) 2005-07-07 2016-05-17 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
WO2007008848A2 (en) * 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
US8163792B2 (en) 2006-05-16 2012-04-24 Pharmascience Inc. IAP BIR domain binding compounds
US20080003652A1 (en) * 2006-06-28 2008-01-03 Hans Iding Novel enzymatic process for the manufacture of Boc-Dap-Oh priority to related application(s)
JP5469600B2 (ja) 2007-07-16 2014-04-16 ジェネンテック， インコーポレイテッド 抗ＣＤ７９ｂ抗体及びイムノコンジュゲートとその使用方法
TW200918089A (en) 2007-07-16 2009-05-01 Genentech Inc Humanized anti-CD79b antibodies and immunoconjugates and methods of use
SI2657253T1 (sl) 2008-01-31 2017-10-30 Genentech, Inc. Protitelesa proti CD79b in imunokonjugati in postopki za uporabo
NO2842575T3 (es) 2008-03-18 2018-02-24
CN102933231B (zh) 2010-02-10 2015-07-29 伊缪诺金公司 Cd20抗体及其用途
ES2625637T3 (es) 2010-02-12 2017-07-20 Pharmascience Inc. Compuestos de unión al dominio BIR IAP
ES2528956T3 (es) 2010-06-10 2015-02-13 Seattle Genetics, Inc. Nuevos derivados de auristatina y su uso
WO2012041805A1 (de) 2010-09-29 2012-04-05 Bayer Pharma Aktiengesellschaft N-carboxyalkyl-auristatine und ihre verwendung
CN103764667B (zh) * 2011-03-16 2017-06-20 西雅图基因公司 N‑羧烷基耳他汀类及其应用
MX371526B (es) * 2011-05-27 2020-01-31 Ambrx Inc Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales.
MX359217B (es) 2011-05-27 2018-09-19 Ambrx Inc Composiciones que contienen, métodos que involucran, y usos de derivados de dolastatina unidos a aminoácidos no naturales.
AU2013318779B2 (en) 2012-09-20 2016-07-28 Celltrion, Inc. Dolastatin-10 derivative, method of producing the same and anticancer drug composition containing the same
CA2935077C (en) 2013-12-27 2022-03-15 Geoffrey C. Winters Sulfonamide-containing linkage systems for drug conjugates
PL3262071T3 (pl) 2014-09-23 2020-08-10 F. Hoffmann-La Roche Ag Sposób stosowania immunokoniugatów anty-CD79b
CN105949277B (zh) * 2015-05-05 2019-03-01 成都永泰诺科技有限公司 一种抗肿瘤化合物及其用途
US10792365B2 (en) * 2016-03-29 2020-10-06 Toray Industries, Inc. Peptide derivative and use thereof
CN109021065B (zh) * 2017-06-08 2021-10-01 复旦大学 一种制备海兔毒素Dolastatin10的方法
CA3230737A1 (en) 2021-09-03 2023-03-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides

Also Published As

Publication number Publication date
JP2004534859A (ja) 2004-11-18
RU2004105145A (ru) 2005-07-10
NZ530655A (en) 2006-08-31
US20030055002A1 (en) 2003-03-20
DK1412328T3 (da) 2007-02-12
CN1553897A (zh) 2004-12-08
NO20040198L (no) 2004-02-19
WO2003008378A1 (en) 2003-01-30
KR20060057652A (ko) 2006-05-26
RU2296750C2 (ru) 2007-04-10
DE60215179T2 (de) 2007-10-18
EP1412328B1 (en) 2006-10-04
IL159890A0 (en) 2004-06-20
MY127718A (en) 2006-12-29
SI1412328T1 (sl) 2007-02-28
PL367682A1 (en) 2005-03-07
HUP0401253A2 (hu) 2004-12-28
EP1412328A1 (en) 2004-04-28
ATE341537T1 (de) 2006-10-15
ES2272763T3 (es) 2007-05-01
ZA200400334B (en) 2005-06-29
PT1412328E (pt) 2007-01-31
US6737409B2 (en) 2004-05-18
PE20030258A1 (es) 2003-03-19
BR0211289A (pt) 2004-08-03
KR100611540B1 (ko) 2006-08-10
HRP20040043A2 (en) 2004-08-31
DE60215179D1 (de) 2006-11-16
KR20040023661A (ko) 2004-03-18
GT200200154A (es) 2003-05-16
CO5550462A2 (es) 2005-08-31
CA2453987A1 (en) 2003-01-30
MXPA04000577A (es) 2004-04-20
UY27388A1 (es) 2003-01-31
AR036175A1 (es) 2004-08-18

Similar Documents

Publication Publication Date Title
PA8551001A1 (es) Nuevos compuestos
AR023574A1 (es) Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
CR6726A (es) Compuestos azapoliciclicos condensados con arilo
PA8432901A1 (es) Compuestos de piridilpirrol
ECSP034444A (es) Derivados de 4-amino-6-fenil-pirrolo(2,3-d)pirimidina
CO4810375A1 (es) Derivados de 9-amino-3-ceto eritromicina
PA8593001A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
UY28510A1 (es) Compuestos quimicos
BR0113838A (pt) Derivados de n-fenil-2-pirimidina-amina
ECSP055671A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesteresa
BR122019010008B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
AR027548A1 (es) Derivados de amino pirazol utiles para el tratamiento de la obesidad y otros desordenes
UY27368A1 (es) Nuevos compuestos
AR037517A1 (es) Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
UY26872A1 (es) Derivados de la 4- fenil piridina
PA8580301A1 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
AR022469A1 (es) Uso de acidos isoxazolcarboxilicos sustituidos y derivados y nuevas sustancias
ECSP045148A (es) Formas de sal e-2-metoxi-n-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi)fenilamino]quinazolin-6-il}alil]acetamida, y su preparación y uso contra el cancer
PA8495101A1 (es) Derivados de 13-metileritromicina
RS99804A (en) Novel compounds and their use
UY27455A1 (es) Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos.
BR0314195A (pt) Derivados de piridina substituìda como agentes antitumorais
UY27593A1 (es) Nuevos compuestos
PA8568101A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso
UY27980A1 (es) Indoles 2,7-sustituidos